Validation of AML Proteomic Signature Associated With Clinical Response to Ara-C Based Induction Therapy in Patients 60 Years of Age or Older Using Samples From ECOG Studies 3999, 3993 and 1490
OBJECTIVES:
Primary
- To validate a pre-specified proteomic classifier to predict the likelihood of complete
response (CR) to cytarabine-based induction chemotherapy in older patients with non-M3
acute myeloid leukemia.
Secondary
- To identify signaling nodes associated with risk of relapse among these patients who
achieve a CR to induction chemotherapy.
OUTLINE: This is a multicenter study.
Previously collected bone marrow and peripheral blood samples are analyzed to validate the
association of a pre-specified proteomic signature with clinical response via flow
cytometry.
Observational
N/A
Proportion of patients achieving a complete response to induction chemotherapy
No
Elisabeth Paietta, PhD
Principal Investigator
Our Lady of Mercy Medical Center Comprehensive Cancer Center
Unspecified
CDR0000681533
NCT01169363
October 2009
Name | Location |
---|